Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (106)
2024
-
Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Genes and Immunity
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
Journal for immunotherapy of cancer, Vol. 12, Núm. 5
-
Tumor slice culture system for ex vivo immunotherapy studies
Methods in Cell Biology (Academic Press Inc.)
2023
-
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
Frontiers in Immunology, Vol. 14
-
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
Annals of Oncology
-
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77
-
The Lymphatic Endothelium in the Context of Radioimmuno-Oncology
Cancers, Vol. 15, Núm. 1
2022
-
Cancer vaccines: the next immunotherapy frontier
Nature Cancer, Vol. 3, Núm. 8, pp. 911-926
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
-
Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490
-
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
-
IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
2020
-
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Drug Resistance Updates, Vol. 53